Discovers and develops immuno-oncology therapeutics designed to harness the body's immune system to fight cancer. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 12.8× for every dollar of annual revenue.
Analysts' average target sits 79% above today's price.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.
An investor who bought at the very peak is down 79% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $35M a year. A small number, but proof the product has real buyers.
There is $494.6M in the vault; even if every debt were paid off, $489.6M would remain.
A loss of $134.4M against $35M in annual sales.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
Right now the product sells for less than it costs to make; every sale deepens the loss. Council score: 3/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.